The following is a summary of the Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Arcturus reported Q1 2024 revenues of $38 million, an increase from $30.9 million in Q4 2023.

• Operating expenses were at $68.4 million for Q1 2024, a hike from $49.1 million in the previous quarter.

• They reported a net loss of $26.8 million or $1 per share in Q1 2024.

• Cashed at $345.3 million as of March 2024.

Business Progress:

• The company is set to deliver 4 million doses of Kostaive, a COVID-19 vaccine, to Japan in Q3 2024.

• The ARCT-810 program for OTC deficiency showed favourable results, and a Phase 2 study was initiated.

• The company started a Phase 3 study with ARCT-2303, a vaccine candidate for the Omicron variant.

• An investment acceleration in the mRNA vaccine and therapeutics production facility is planned.

• Expectations of substantial revenues from Kostaive's commercialization in Japan are on the horizon, with a potential price of $100 per dose. The company's profit share with partners is 60/40 on a gross profit basis.

• The ARCALIS facility in Japan is geared to deliver 4 million doses of a vaccine by Q3 and the company is exploring ways to monetize its stake in ARCALIS.

More details: Arcturus Therapeutics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.